Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Simba Gill received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, subject to continued service on the board, and expire on June 23, 2036. Following this award, Gill holds 28,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GILL SIMBA

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Underlying shares: 28,000 shares +2 more

5 metrics

Options granted 28,000 options Grant of stock options to director Simba Gill

Exercise price $4.08 per share Strike price for Simba Gill’s stock options

Underlying shares 28,000 shares Common stock underlying the options

Expiration date June 23, 2036 Option term end for the grant

Post-grant holdings 28,000 options Total options held directly after transaction

Key Terms

Stock Options (Right to buy), Grant, award, or other acquisition, board of directors

3 terms

Stock Options (Right to buy) financial

"security_title: "Stock Options (Right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

board of directors financial

"continued service on the board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:02 PM Accepted by SEC EDGAR 06/25/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILL SIMBA

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Balkrishan (Simba) Gill	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Foghorn Therapeutics (FHTX) report for Simba Gill?

Foghorn Therapeutics reported that director Simba Gill received a grant of stock options for 28,000 shares. The options give him the right to buy common stock at an exercise price of $4.08 per share, subject to vesting conditions and an expiration date.

What are the key terms of Simba Gill’s new FHTX stock options?

Simba Gill received 28,000 stock options to buy Foghorn Therapeutics common stock at $4.08 per share. The options vest in full one year after the grant date, assuming continued board service, and expire on June 23, 2036 if not exercised earlier.

When do Simba Gill’s Foghorn Therapeutics options vest?

The options granted to Simba Gill vest in full on the first anniversary of the grant date. Vesting is conditioned on his continued service on Foghorn Therapeutics’ board of directors through that one-year mark, according to the transaction footnote.

What is the expiration date of Simba Gill’s FHTX stock options?

Simba Gill’s stock options expire on June 23, 2036 if not exercised. After that expiration date, the right to buy 28,000 shares of Foghorn Therapeutics common stock at $4.08 per share will lapse under the option grant terms.

How many FHTX options does Simba Gill hold after this transaction?

After this grant, Simba Gill holds 28,000 stock options directly. These options each relate to one share of Foghorn Therapeutics common stock and have an exercise price of $4.08 per share, as shown in the insider transaction details.